The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

The CTPA/siCSF1R system consists of a triblock polyamino acid (TPA) gene vector encapsulating siRNA, which is conjugated to the surface of photosynthetic cyanobacteria. It utilizes the inherent ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

In SNALPs, the backbone-modified siRNA is encapsulated within a closed shell of a cationic-zwitterionic lipid bilayer, furnished with an outer PEG shield (Figure 2A). The lipid bilayer contains a ...

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic ...

证券之星消息，根据天眼查APP数据显示凯莱英（002821）新获得一项发明专利授权，专利名为“抑制FXI基因表达的siRNA的制备方法”，专利申请号为CN202410921752.5，授权日为2025年1月28日。

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug ...

Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B Format: Oral Presentation Presentation Number: OR10 Date: 7 th February 2025 Session: SLAM e-therapeutics plc ("ETX") ...